Pharmacokinetic (PK) analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone- refractory prostate cancer (HRPC) who progressed after docetaxel treatment

J.-P. Droz,Aude Flechon,Florence Joly,H. de Mont-Serrat,Rolf Kaiser,Peter Stopfer,S. Oudard

Pharmacokinetic (PK) analysis of two dosing schedules of the angiokinase inhibitor BIBF 1120 in patients with hormone- refractory prostate cancer (HRPC) who progressed after docetaxel treatment

2008

J.-P. Droz
Aude Flechon
Florence Joly
H. de Mont-Serrat
Rolf Kaiser
Peter Stopfer
S. Oudard

14578 Background: BIBF 1120 is a novel, oral, potent angiokinase inhibitor blocking the VEGFR 1/2/3, FGFR 1/3, and PDGFR α/β tyrosine kinases at nanomolar concentrations. This randomized, open-labe...

Keywords:

Dosing
Oncology
Hormone refractory prostate cancer
Medicine
Internal medicine
Docetaxel
Pharmacokinetics
Fibroblast growth factor receptor
in patient
VEGF receptors
dosing schedules
Tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations